Michael Nally is the founder of Generate Biomedicines. Generate Biomedicines has raised $750M in total funding. Latest round: IPO.
Michael Nally is the CEO of Generate:Biomedicines, a role he took on in 2021. He has guided the company through Series B and Series C financings, as well as an Amgen research collaboration. Nally also oversaw the company's IPO in 2026 and has spoken about the company's clinical progress, including its first asset entering the clinic in late 2023.
Full founder directory · Investor directory · Company funding database · Fundraising library